CTOs on the Move

Integrated Translational Health Research Institu

www.ithriv.org

 
The integrated Translational Health Research Institute of Virginia (iTHRIV), at the University of Virginia School of Medicine, will increase capacity of the broad iTHRIV research community to address a wide range of clinical and translational research questions.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ithriv.org
  • 560 Ray C. Hunt Drive Rm 2156 PO Box 800751
    Charlottesville, VA USA 22903
  • Phone: 434.924.6208

Executives

Name Title Contact Details

Funding

Integrated Translational Health Research Institute of Virginia raised $23M on 03/05/2019

Similar Companies

Medical Imaging Center of Southern California

Medical Imaging Center of Southern California is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Excel Imaging

Excel Imaging is a Winston Salem, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allied Diagnostic Imaging Resources

Allied Diagnostic Imaging Resources is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prosthodent Dental Studio

Prosthodent Dental Studio is a Clinton Township, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zai Lab

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Headquartered in Shanghai since our founding in 2014, our experienced team has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on our extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development. Through these partnerships, Zai Lab has built the strongest late stage oncology portfolio with global first-in-class and/or best-in-class profile, among innovative Chinese biotech companies. We are further supplementing our pipeline with an in-house discovery effort aiming to produce 1-2 global INDs per year. Zai Lab is rapidly expanding into a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing innovative medicines. To that end, we have built our internal R&D center to advance our discovery pipeline, a strong clinical development and operations team, and our own manufacturing facilities in China. We have also established a highly specialized commercial team to support marketing of our innovative products in China. We believe this integrated approach will provide sustainable competitive advantages for Zai Lab. Zai Lab was successfully listed on the Nasdaq Stock Market in September 2017. Since then, Zai Lab significantly expanded with several offices across China and opened its U.S. headquarters in San Francisco in December 2018. As of December 2019, the Company has a global team of approximately 700 employees.